The Cancer Beam America Doesn't Have Yet: Japan's 30-Year Lead in Carbon Ion Therapy

Picture a form of radiation that can be aimed with the precision of a scalpel — depositing most of its destructive energy directly inside a tumor while sparing the healthy tissue in front of and behind it. In Japan, this has been available to cancer patients since June 1994. In the United States, as of today, it does not exist outside of research proposals and a construction site in Florida.

The technology is called carbon ion radiotherapy (CIRT), sometimes described as “heavy ion therapy.” It is one of the starkest examples of the gap between what Japanese and American patients can access — not because the science is unproven, but because of decades of divergent infrastructure investment.

How it works

Conventional radiotherapy uses X-rays, which deposit energy along their entire path through the body — damaging tissue in front of and behind the tumor, not just inside it. Carbon ion therapy instead accelerates carbon nuclei to nearly 70% the speed of light and directs them at the tumor. These heavier particles release the bulk of their energy in a sharp, controllable burst — the Bragg peak — right at the target depth, then stop. The result is a treatment that can strike deep, hard-to-reach, and radiation-resistant tumors, such as certain sarcomas and adenocarcinomas, while reducing damage to surrounding organs.

A practical benefit follows from the precision: treatment courses are often dramatically shorter than conventional radiation. Some liver and lung tumors have been treated in a single session, and localized prostate cancer — which can take eight or nine weeks with standard radiotherapy — has been treated in about three weeks at Japanese centers.

Where each country stands

Japan pioneered clinical use of carbon ion therapy at the National Institute of Radiological Sciences (NIRS) in Chiba, starting in 1994. More than 9,000 patients had been treated there by 2015 alone. Japan’s national health insurance now covers CIRT for a defined set of indications, including pediatric solid tumors, inoperable bone and soft tissue sarcomas, certain head and neck cancers, and prostate cancer — with coverage expanding further in 2024 to include early-stage lung tumors and larger hepatocellular carcinomas. As of 2024, Japan operates the most carbon ion facilities of any country in the world, part of a national network of 26 particle therapy institutions.

The United States has never had an operational carbon ion facility. Worldwide, roughly 37,500 patients were treated with CIRT between 1994 and 2020 — and only 15 of them were U.S. citizens, most of whom had to travel abroad. That is beginning to change: in early 2026, Mayo Clinic announced it will build the Western Hemisphere’s first carbon ion therapy center in Jacksonville, Florida, in partnership with the Japanese equipment maker Hitachi. But the facility is not expected to begin treating patients until 2028, and it will open without a guarantee of FDA approval — Mayo and Hitachi plan to submit clinical data gathered during the facility’s early operation to support eventual clearance. Mayo Clinic researchers estimate that more than 44,000 Americans are diagnosed each year with cancers that could potentially benefit from this treatment, and virtually none of them can access it today.

Why this gap exists

This is not a story about American medicine falling behind broadly — the U.S. remains a global leader in cancer drug development, immunotherapy, and surgical innovation. But carbon ion facilities are enormous, expensive undertakings, requiring particle accelerators the size of a building, and Japan made that national infrastructure investment three decades ago while the U.S. did not. The result is a rare case where a mature, insurance-covered standard of care in one advanced country remains, for now, essentially unreachable in another.

The bigger pattern: prevention

Advanced treatment access is only part of the story. The same national commitment to acting early — treating cancers with unusual precision once found — runs alongside Japan’s tradition of finding them early in the first place, through comprehensive screening programs like the Ningen Dock. Precision when it counts, and thoroughness before symptoms appear, are two sides of the same philosophy.

We’ll keep tracking these gaps — the drugs, procedures, and preventive approaches where Japan is ahead — here in The Mirai Journal each week.

Sources: National Effort to Re-Establish Heavy Ion Cancer Therapy in the United States — Frontiers in Oncology; The Majority of United States Citizens With Cancer do not Have Access to Carbon Ion Radiotherapy — PubMed; Twenty Years of Carbon Ion Radiation Therapy at the National Institute of Radiological Sciences — PMC; Current status of national health insurance systems for advanced radiation technologies in Korea and Japan — PMC; Mayo Clinic to Build North America’s First Carbon Ion Therapy Facility — Mayo Clinic Comprehensive Cancer Center Blog; Jacksonville Snags Western Hemisphere’s First Carbon Ion Cancer Center — Hoodline.